Results 321 to 330 of about 4,836,823 (371)

Corrigendum to "Herceptin-Mediated Cardiotoxicity: Assessment by Cardiovascular Magnetic Resonance". [PDF]

Cardiol Res Pract
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Therapeutic potential of chalcones as cardiovascular agents

Life Sciences, 2016
Cardiovascular diseases are the leading cause of death affecting 17.3 million people across the globe and are estimated to affect 23.3 million people by year 2030. In recent years, about 7.3 million people died due to coronary heart disease, 9.4 million deaths due to high blood pressure and 6.2 million due to stroke, where obesity and atherosclerotic ...
Debarshi Kar Mahapatra, Sanjay Kumar Bharti   +1 more
openaire   +4 more sources

Cardiovascular Protection with Anti-hyperglycemic Agents

American Journal of Cardiovascular Drugs, 2019
Diabetes mellitus is a major risk factor for cardiovascular (CV) disease. Conversely, CV disease is responsible for a majority of the deaths in patients with diabetes. Many drug trials have concentrated on blood glucose (hemoglobin A1c) reduction. This strategy, while reducing microvascular outcomes like nephropathy and neuropathy, has little or no ...
Prakash Deedwania, Tushar Acharya
openaire   +4 more sources

Quinazoline cardiovascular agents (review)

Pharmaceutical Chemistry Journal, 1982
The chemistry of quinazoline compounds has a more than centuries-old history; however, the intensive search for biologically active substances in this series began only in the last few decades. The establishment of the quinazoline structure of the antimalarial alkaloid febrifugine [i], which was isolated from the Chinese plant aseru (Dichroa febrifuga ...
O. N. Volzhina, L. N. Yakhontov
openaire   +3 more sources

Methods for Identifying Cardiovascular Agents: A Review

Recent Patents on Cardiovascular Drug Discovery, 2006
Basic and clinical investigation into many of the diverse aspects of cardiovascular drug discovery employs varied approaches aimed at determining physiologic and pathophysiologic efficacy of candidate agents for therapeutic utility with the ultimate hope of identifying those agents capable of exerting salutary influence upon cardiac and vascular ...
D. Tulis
openaire   +4 more sources

Intranasal delivery of cardiovascular agents: An innovative approach to cardiovascular pharmacotherapy

American Heart Journal, 1994
The intranasal administration of drugs has long been used for the topical treatment of various nasal disorders. Many features of the intranasal mucosa also make it useful for delivery of systemically active agents. It has been shown that intranasal drug administration can provide plasma drug levels similar to those observed with comparable doses of ...
William H. Frishman, Andre J. Landau, Robert T. Eberhardt   +2 more
openaire   +3 more sources

Cardiovascular adjustment to antiadrenergic agents

The American Journal of Medicine, 1983
A common target organ involvement associated with essential hypertension is left ventricular hypertrophy. A number of, but not all, effective antihypertensive drugs will regress left ventricular hypertrophy. Our attention has focused on the hemodynamic characteristics of those drugs that either directly or indirectly alter sympathetic nervous activity.
Edward D. Frohlich, Barbara L. Pegram
openaire   +3 more sources

Oral Antidiabetic Agents and Cardiovascular Outcomes

Current Problems in Cardiology, 2018
Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes; however, a direct protective effect of tight glycemic control remains unproven. In fact, until 2008, when concerns related to rosiglitazone prompted regulatory agencies to mandate assessment of cardiovascular safety of new antidiabetic agents ...
Pareek, Manan, Bhatt, Deepak L
openaire   +4 more sources